Iron Metabolism: Regulation and Diseases, Department of Basic Sciences, Universitat Internacional de Catalunya (UIC), 08195 Sant Cugat del Vallès, Spain.
BloodGenetics S.L. Diagnostics in Inherited Blood Diseases, 08950 Esplugues de Llobregat, Spain.
Int J Mol Sci. 2022 Apr 15;23(8):4406. doi: 10.3390/ijms23084406.
Divalent metal-iron transporter 1 (DMT1) is a mammalian iron transporter encoded by the SLC11A2 gene. DMT1 has a vital role in iron homeostasis by mediating iron uptake in the intestine and kidneys and by recovering iron from recycling endosomes after transferrin endocytosis. Mutations in SLC11A2 cause an ultra-rare hypochromic microcytic anemia with iron overload (AHMIO1), which has been described in eight patients so far. Here, we report two novel cases of this disease. The first proband is homozygous for a new SLC11A2 splicing variant (c.762 + 35A > G), becoming the first ever patient reported with a SLC11A2 splicing mutation in homozygosity. Splicing studies performed in this work confirm its pathogenicity. The second proband harbors the previously reported DMT1 G75R mutation in homozygosis. Functional studies with the G75R mutation in HuTu 80 cells demonstrate that this mutation results in improper DMT1 accumulation in lysosomes, which correlates with a significant decrease in DMT1 levels in patient-derived lymphoblast cell lines (LCLs). We also suggest that recombinant erythropoietin would be an adequate therapeutic approach for AHMIO1 patients as it improves their anemic state and may possibly contribute to mobilizing excessive hepatic iron.
二价金属铁转运蛋白 1(DMT1)是一种由 SLC11A2 基因编码的哺乳动物铁转运蛋白。DMT1 通过介导肠道和肾脏中的铁摄取以及通过转铁蛋白内吞作用后从再循环内体回收铁,在铁稳态中起着至关重要的作用。SLC11A2 中的突变导致一种极罕见的低色素性小细胞性贫血伴铁过载(AHMIO1),迄今为止已在 8 名患者中描述过。在这里,我们报告了两例该病的新病例。第一例先证者为新的 SLC11A2 剪接变异体(c.762 + 35A > G)纯合子,成为首例报道的 SLC11A2 剪接突变纯合子患者。本工作中进行的剪接研究证实了其致病性。第二位先证者携带先前报道的 DMT1 G75R 突变纯合子。在 HuTu 80 细胞中对 G75R 突变进行的功能研究表明,该突变导致 DMT1 在溶酶体中的异常积累,这与患者来源的淋巴母细胞系(LCL)中 DMT1 水平的显著下降相关。我们还提出,重组促红细胞生成素将是 AHMIO1 患者的一种合适的治疗方法,因为它可以改善他们的贫血状态,并可能有助于动员过多的肝铁。